• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.

作者信息

Verma Subodh, Mazer C David, Bhatt Deepak L, Raj Satish R, Yan Andrew T, Verma Atul, Ferrannini Ele, Simons Gudrun, Lee Jisoo, Zinman Bernard, George Jyothis T, Fitchett David

机构信息

Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada

Department of Anesthesia, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

出版信息

Diabetes Care. 2019 Mar;42(3):e42-e44. doi: 10.2337/dc18-1959. Epub 2019 Jan 23.

DOI:10.2337/dc18-1959
PMID:30674547
Abstract
摘要

相似文献

1
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.恩格列净与2型糖尿病合并左心室肥厚患者的心血管结局：EMPA-REG OUTCOME试验的亚组分析
Diabetes Care. 2019 Mar;42(3):e42-e44. doi: 10.2337/dc18-1959. Epub 2019 Jan 23.
2
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.2型糖尿病患者降低血压对心血管结局和死亡率的影响：聚焦于钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和恩格列净心血管结局研究（EMPA-REG OUTCOME）
Diabetes Res Clin Pract. 2016 Nov;121:204-214. doi: 10.1016/j.diabres.2016.09.016. Epub 2016 Sep 28.
3
Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.恩格列净在EMPA-REG OUTCOME试验中利尿作用的重新评估：与经典利尿剂的比较。
Diabetes Metab. 2016 Sep;42(4):224-33. doi: 10.1016/j.diabet.2016.05.006. Epub 2016 Jun 10.
4
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.降低血压对2型糖尿病患者肾脏结局的影响：聚焦于钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和恩格列净心血管结局研究（EMPA-REG OUTCOME）
Diabetes Metab. 2017 Apr;43(2):99-109. doi: 10.1016/j.diabet.2016.12.010. Epub 2017 Jan 30.
5
[EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].[恩格列净心血管结局研究：恩格列净降低心血管高危2型糖尿病患者的死亡率]
Rev Med Liege. 2015 Nov;70(11):583-9.
6
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.CANVAS和EMPA-REG心血管结局试验中2型糖尿病（T2DM）患者报告的结局相关成本的经济模型。
J Med Econ. 2019 Mar;22(3):280-287. doi: 10.1080/13696998.2018.1562817. Epub 2019 Jan 11.
7
Impact of EMPA-REG OUTCOME on the management of type 2 diabetes mellitus: a review for primary care physicians.恩格列净心血管结局研究（EMPA-REG OUTCOME）对2型糖尿病管理的影响：基层医疗医生综述
Postgrad Med. 2016 Nov;128(8):822-827. doi: 10.1080/00325481.2016.1245093. Epub 2016 Oct 25.
8
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.恩格列净治疗心血管高危2型糖尿病患者的心力衰竭结局：EMPA-REG OUTCOME®试验结果
Eur Heart J. 2016 May 14;37(19):1526-34. doi: 10.1093/eurheartj/ehv728. Epub 2016 Jan 26.
9
EMPA-REG OUTCOME: The Cardiologist's Point of View.恩格列净心血管结局研究（EMPA-REG OUTCOME）：心脏病专家的观点
Am J Med. 2017 Jun;130(6S):S57-S62. doi: 10.1016/j.amjmed.2017.04.006.
10
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.恩格列净对 2 型糖尿病合并已确诊心血管疾病患者的尿白蛋白与肌酐比值的影响：来自 EMPA-REG OUTCOME 随机、安慰剂对照试验的探索性分析。
Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1. Epub 2017 Jun 27.

引用本文的文献

1
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂用于慢性肾脏病和糖尿病患者。
Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
2
Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.比较 2 型糖尿病和心力衰竭患者中不同 SGLT2 抑制剂的心血管获益：一项随机对照试验的系统评价和网络荟萃分析。
Front Endocrinol (Lausanne). 2023 Dec 20;14:1216160. doi: 10.3389/fendo.2023.1216160. eCollection 2023.
3
Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin.
恩格列净治疗患者的左心室质量预测心脏逆重构。
Cardiovasc Diabetol. 2023 Jun 28;22(1):152. doi: 10.1186/s12933-023-01849-w.
4
Metabolic Syndrome and Cardiac Remodeling Due to Mitochondrial Oxidative Stress Involving Gliflozins and Sirtuins.代谢综合征与心脏重构：涉及格列净类药物和 Sirtuins 的线粒体氧化应激
Curr Hypertens Rep. 2023 Jun;25(6):91-106. doi: 10.1007/s11906-023-01240-w. Epub 2023 Apr 13.
5
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.心血管结局试验：2 型糖尿病当前管理模式的重大转变。
Cardiovasc Diabetol. 2022 Aug 4;21(1):144. doi: 10.1186/s12933-022-01575-9.
6
Clinical Evidence and Proposed Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?钠-葡萄糖协同转运蛋白2抑制剂在射血分数保留的心力衰竭中的临床证据及潜在机制：是否存在类效应？
Card Fail Rev. 2022 Jun 29;8:e23. doi: 10.15420/cfr.2022.11. eCollection 2022 Jan.
7
Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention.恩格列净低剂量对经皮冠状动脉介入治疗后 2 型糖尿病合并急性冠状动脉综合征患者短期结局的影响。
Saudi Med J. 2022 May;43(5):458-464. doi: 10.15537/smj.2022.43.5.20220018.
8
Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention.糖尿病性心肌病中的左心室肥厚：一个干预靶点。
Front Cardiovasc Med. 2021 Sep 29;8:746382. doi: 10.3389/fcvm.2021.746382. eCollection 2021.
9
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.钠-葡萄糖协同转运蛋白 2 抑制剂对肾脏和心血管功能的影响。
Annu Rev Physiol. 2021 Feb 10;83:503-528. doi: 10.1146/annurev-physiol-031620-095920. Epub 2020 Nov 16.
10
Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors.2型糖尿病患者的神经张力与心肾结局：聚焦于钠-葡萄糖协同转运蛋白2抑制剂的文献综述
Heart Fail Rev. 2021 May;26(3):643-652. doi: 10.1007/s10741-020-10046-w. Epub 2020 Nov 9.